Global Blood Therapeutics Inc (GBT) Expected to Post Earnings of -$0.87 Per Share

Wall Street brokerages expect Global Blood Therapeutics Inc (NASDAQ:GBT) to announce earnings per share (EPS) of ($0.87) for the current quarter, Zacks reports. Zero analysts have provided estimates for Global Blood Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.96) and the highest estimate coming in at ($0.79). Global Blood Therapeutics posted earnings of ($0.55) per share during the same quarter last year, which would indicate a negative year over year growth rate of 58.2%. The firm is expected to announce its next quarterly earnings results on Monday, August 6th.

On average, analysts expect that Global Blood Therapeutics will report full year earnings of ($3.62) per share for the current financial year, with EPS estimates ranging from ($4.27) to ($3.23). For the next year, analysts forecast that the company will post earnings of ($3.90) per share, with EPS estimates ranging from ($4.39) to ($3.11). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow Global Blood Therapeutics.

Get Global Blood Therapeutics alerts:

Global Blood Therapeutics (NASDAQ:GBT) last issued its earnings results on Monday, May 7th. The company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.04. During the same period last year, the business earned ($0.60) earnings per share.

Several brokerages have weighed in on GBT. BidaskClub lowered Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, April 4th. HC Wainwright set a $73.00 price objective on Global Blood Therapeutics and gave the company a “buy” rating in a report on Thursday, May 24th. Wedbush reissued an “outperform” rating and set a $70.00 price objective on shares of Global Blood Therapeutics in a report on Monday, June 18th. Cantor Fitzgerald set a $69.00 price objective on Global Blood Therapeutics and gave the company a “buy” rating in a report on Wednesday, May 9th. Finally, Morgan Stanley lowered Global Blood Therapeutics from an “overweight” rating to an “equal weight” rating and set a $61.00 price objective on the stock. in a report on Wednesday, March 21st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Global Blood Therapeutics currently has an average rating of “Buy” and an average price target of $69.62.

In other news, insider Jung Choi sold 3,000 shares of the stock in a transaction dated Thursday, May 17th. The stock was sold at an average price of $48.25, for a total transaction of $144,750.00. Following the transaction, the insider now owns 136,077 shares of the company’s stock, valued at approximately $6,565,715.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.40% of the company’s stock.

A number of large investors have recently made changes to their positions in GBT. Perceptive Advisors LLC boosted its stake in Global Blood Therapeutics by 14.7% during the 4th quarter. Perceptive Advisors LLC now owns 4,889,066 shares of the company’s stock valued at $192,384,000 after purchasing an additional 625,000 shares during the period. Franklin Resources Inc. bought a new stake in Global Blood Therapeutics during the 1st quarter valued at approximately $30,023,000. RTW Investments LP boosted its stake in Global Blood Therapeutics by 2,186.9% during the 4th quarter. RTW Investments LP now owns 601,683 shares of the company’s stock valued at $23,676,000 after purchasing an additional 575,373 shares during the period. Millennium Management LLC boosted its stake in Global Blood Therapeutics by 4,463.4% during the 4th quarter. Millennium Management LLC now owns 479,838 shares of the company’s stock valued at $18,882,000 after purchasing an additional 469,323 shares during the period. Finally, Citadel Advisors LLC boosted its stake in Global Blood Therapeutics by 161.7% during the 4th quarter. Citadel Advisors LLC now owns 716,611 shares of the company’s stock valued at $28,199,000 after purchasing an additional 442,828 shares during the period. Hedge funds and other institutional investors own 95.54% of the company’s stock.

Global Blood Therapeutics traded up $0.70, hitting $42.05, during mid-day trading on Friday, Marketbeat reports. The stock had a trading volume of 2,105,744 shares, compared to its average volume of 938,717. Global Blood Therapeutics has a 1-year low of $24.02 and a 1-year high of $68.05. The firm has a market cap of $2.14 billion, a P/E ratio of -15.24 and a beta of 4.40.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is voxelotor, an oral once-daily therapy that modulates hemoglobin's affinity for oxygen, which is in Phase III clinical trials in adult and adolescent patients with sickle cell disease (SCD).

Get a free copy of the Zacks research report on Global Blood Therapeutics (GBT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Global Blood Therapeutics (NASDAQ:GBT)

Leave a Reply

Your email address will not be published. Required fields are marked *